ProfileGDS5678 / 1449392_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 60% 59% 59% 60% 59% 58% 63% 59% 59% 60% 59% 59% 59% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5788259
GSM967853U87-EV human glioblastoma xenograft - Control 23.5663360
GSM967854U87-EV human glioblastoma xenograft - Control 33.5567659
GSM967855U87-EV human glioblastoma xenograft - Control 43.5107459
GSM967856U87-EV human glioblastoma xenograft - Control 53.5448160
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6389859
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5994458
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7964663
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.527359
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5470159
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5748760
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.533659
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5676359
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5575659